NPC1 regulates the distribution of phosphatidylinositol 4-kinases at Golgi and lysosomal membranes

Candice Kutchukian  
*University of California, Davis*

Oscar Vivas  
*University of California, Davis*

Maria Casas  
*University of California, Davis*

Julia G Jones  
*University of California, Davis*

Scott A Tiscione  
*University of California, Davis*

*See next page for additional authors*

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

*Please let us know how this document benefits you.*

**Recommended Citation**

Kutchukian, Candice; Vivas, Oscar; Casas, Maria; Jones, Julia G; Tiscione, Scott A; Simó, Sergi; Ory, Daniel S; Dixon, Rose E; and Dickson, Eamonn J, "NPC1 regulates the distribution of phosphatidylinositol 4-kinases at Golgi and lysosomal membranes." The EMBO journal. 40, 13. e105990 (2021). https://digitalcommons.wustl.edu/open_access_pubs/10826

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
NPC1 regulates the distribution of phosphatidylinositol 4-kinases at Golgi and lysosomal membranes

Candice Kutchukian1,†, Oscar Vivas1,‡,‡, Maria Casas1, Julia G Jones1, Scott A Tiscione1, Sergi Simó2, Daniel S Ory3, Rose E Dixon1,‡ & Eamonn J Dickson1,*

Abstract

Cholesterol and phosphoinositides (PI) are two critically important lipids that are found in cellular membranes and dysregulated in many disorders. Therefore, uncovering molecular pathways connecting these essential lipids may offer new therapeutic insights. We report that loss of function of lysosomal Niemann-Pick Type C1 (NPC1) cholesterol transporter, which leads to neurodegenerative NPC disease, initiates a signaling cascade that alters the cholesterol/phosphatidylinositol 4-phosphate (PtdIns4P) countertransport cycle between Golgi-endoplasmic reticulum (ER), as well as lysosome-ER membrane contact sites (MCS). Central to these disruptions is increased recruitment of phosphatidylinositol 4-kinases—PI4KIIα and PI4KIIIβ—which boosts PtdIns4P metabolism at Golgi and lysosomal membranes. Aberrantly increased PtdIns4P levels elevate constitutive anterograde secretion from the Golgi complex, and mTORC1 recruitment to lysosomes. NPC1 disease mutations phenocopy the transporter loss of function and can be rescued by inhibition or knockdown of either key phosphoinositide enzymes or their recruiting partners. In summary, we show that the lysosomal NPC1 cholesterol transporter tunes the molecular content of Golgi and lysosome MCS to regulate intracellular trafficking and growth signaling in health and disease.

Keywords membrane contact sites; mTORC; neurodegeneration; Niemann-Pick Type C; phosphoinositides

Subject Categories Membranes & Trafficking; Organelles

DOI 10.15252/embj.2020105990 | Received 22 June 2020 | Revised 11 March 2021 | Accepted 19 March 2021 | Published online 21 May 2021

The EMBO Journal (2021) 40: e105990

Introduction

Phosphoinositides are a family of eight phospholipids that define membrane identity by transducing extracellular signals, controlling ion channel function, facilitating cell movement, and orchestrating intracellular trafficking (reviewed, (De Matteis & Godi, 2004; Balla, 2013; Hille et al, 2015; Dickson & Hille, 2019)). Given their importance in coordinating these fundamental cellular events, it is perhaps not surprising that disease mutations or changes in expression of phosphoinositide metabolizing enzymes have been implicated in viral replication (Bishe et al, 2012; Sasaki et al, 2012; McPhail et al, 2019), devastating developmental disorders (Staiano et al, 2015), cancer (Bunney & Katan, 2010; Thapa et al, 2016; Fruman et al, 2017; Waugh, 2019), and neurodegenerative diseases (Leissring et al, 1999; Staiano et al, 2015; Vivas et al, 2019). Thus, understanding mechanisms that regulate and control phosphoinositides is essential from both a cell biological and clinical perspective.

At the Golgi complex, a single mono-phosphorylated species called phosphatidylinositol 4-phosphate (PtdIns4P) predominates and is required for regulated Golgi vesicular trafficking events, signaling and metabolic function, and structural integrity. Golgi PtdIns4P is synthesized by the ATP-dependent phosphorylation of phosphatidylinositol (PtdIns) by Golgi-targeted lipid kinases, termed phosphatidylinositol 4-kinases (PI4K). Four different PI 4-kinases are expressed in most human cells; the type I PI 4-kinase IIIα (PI4KIIα) and PI 4-kinase IIIβ (PI4KIIIβ) enzymes and the structurally distinct type II PI 4-kinases, PI4KIIα and PI4KIIβ (Balla & Balla, 2006). At the Golgi complex, the PI4KIIIβ and PI4KIIα isoforms are the major enzymes responsible for regulating Golgi PtdIns4P-dependent events. Dysregulation of Golgi PtdIns4P metabolism and the PtdIns4P protein interactome features in many cancers and is often associated with tumor progression (Waugh, 2019). Despite evidence linking altered PtdIns4P in cancers, information regarding dysfunctional PtdIns4P metabolism in neurodegenerative diseases is lacking.

In addition to de novo lipid synthesis, target organelle membranes can have lipids transported to them from donor membranes. This form of lipid transport occurs at regions where organelle membranes are less than 20 nm apart, termed membranes contact sites (MCS), and is facilitated by lipid transfer proteins. At
MCS between trans-Golgi network (TGN) and endoplasmic reticulum (ER) (Mesmin et al., 2013), or between the lysosome and ER (Lim et al., 2019), oxyysterol-binding protein (OSBP) mediates the transport of PtdIns4P down its concentration gradient to the ER, fueling the countertransport cycle of cholesterol against its steep concentration gradient (Mesmin et al., 2013). This cholesterol/PtdIns4P exchange contributes to the establishment of a cholesterol gradient between organelles of the secretory pathway and is essential for protein trafficking to the plasma membrane (PM) (Péresse et al., 2020) and mTORC1 recruitment to lysosomes (Lim et al., 2019). At ER-TGN MCS, PI4KIIδ and PI4KIIIδ, as well as an ER PtdIns4P phosphatase (SAC1), maintain the TGN PtdIns4P gradient to perpetuate this exchange cycle (Mesmin et al., 2013; Zewe et al., 2018; Mesmin et al., 2019; Venditti et al., 2019). Likewise, SAC1 and OSBP have also been identified as being essential for cholesterol/PtdIns4P exchange at ER-lysosome MCS. Despite this knowledge, essential information is still unknown, such as (i) the molecular identity of the PI4K that generates PtdIns4P for ER-lysosome lipid transport and (ii) if this molecular choreography is disrupted during pathophysiological conditions.

Here, we report that in Niemann-Pick Type C1 (NPC1) disease, a pathological neurodegenerative disorder of altered cholesterol homeostasis, there is a rearrangement of molecular components of the cholesterol/PtdIns4P cycle. Specifically, we demonstrate that disease mutations or loss of lysosomal NPC1 function leads to the aberrant accumulation of PtdIns4P on Golgi and lysosomal membranes. Underlying altered distribution of PtdIns4P is cholesterol-dependent transcriptional changes in the recruitment machinery of PI4K metabolizing enzymes. Consequences of altered Golgi and lysosomal PtdIns4P are enhanced anterograde trafficking to the PM and mTORC1 recruitment to lysosomes, respectively. We propose that the lysosomal NPC1 cholesterol transporter tunes the molecular elements of both ER-TGN and ER-lysosome MCS in health and disease to regulate trafficking and growth signaling.

Results

Loss of NPC1 function leads to increased Golgi and lysosomal PtdIns4P levels

Niemann-Pick Type C1 (NPC1) is a lysosomal cholesterol transporter that facilitates the egress of cholesterol across the lysosome lumen to other cellular membranes. Inhibition, loss of function, or disease mutations in NPC1 cause the accumulation of lysosomal cholesterol and altered cellular cholesterol homeostasis (Appendix Fig S1A–C). Given the interdependent relationship between cholesterol and PtdIns4P levels at MCS (Antony et al., 2018; Mesmin et al., 2019), we hypothesized that loss of NPC1 function may lead to changes in cellular PtdIns4P levels. To test this hypothesis, we quantified changes in the distribution of the PtdIns4P biosensor P4M (Hammond et al., 2014) under three different NPC1 conditions: inhibition, knockout, and disease mutations. Inhibition of NPC1 using the specific inhibitor U18666A (Lu et al., 2015) (U18) resulted in the significant accumulation of P4M at perinuclear and endolysosomal regions in tsA201 cells (Fig 1A and B) and neurons (Fig 1C and D). To confirm that U18-mediated increases in cellular PtdIns4P were not due to some off-target effect of the U18 compound, we analyzed the distribution of the P4M biosensor in NPC1I1061T cells. Similar to pharmacological inhibition of NPC1, its genetic knockout also resulted in similar PtdIns4P accumulation (Appendix Fig S1D and E). Finally, to determine if elevated PtdIns4P levels are a cellular phenotype of NPC disease, we expressed the P4M biosensor in patient fibroblasts that harbor the most common NPC1 mutation (NPC1I1061T). Similar to U18-treated and NPC1I1061T patient fibroblasts, we significantly increased PtdIns4P levels in perinuclear and endolysosomal regions (Appendix Fig S1F and G). To characterize the subcellular localization of PtdIns4P, we coexpressed P4M with either trans-Golgi network (TGN38-CFP) or lysosomal (LAMP1-RFP) markers in patient fibroblasts. Quantitative analyses revealed that PtdIns4P significantly increased at both TGN (Fig 1E–G) and lysosome membranes (Fig 1H–J and Appendix Fig S1H–J). Increases in Golgi PtdIns4P occurred independently of changes in gross Golgi structure as super-res imaging (resolution ~ 120 nm) of Giantin and TGN46 revealed no significant differences in TGN area from fibroblasts or U18-treated cells (Appendix Fig S1K–M).

To endorse P4M biosensor data, we also quantitatively analyzed phosphoinositide levels across different brain regions of a NPC1I1061T murine model that faithfully recapitulates the most common phenotypes of the human disease (Praggastis et al., 2015). Mass spectrometry lipid analysis of the phosphoinositide composition from four different NPC1I1061T brain regions (mid-brain, hippocampus, cortex, and cerebellum) confirmed significant...
Figure 1.

The EMBO Journal 40: e105990 | 2021 3 of 25

© 2021 The Authors
elevations in global PtdInsP levels relative to wild-type age and sex-matched littermates (Fig 1K). Consistent with NPC1 global brain expression, the increase of PtdInsP in NPC1I1061T brains was not region-specific, with PtdInsP levels significantly elevated across each area, suggesting that the loss of NPC1 function alters the levels of PtdInsP regardless of region. Furthermore, increases in PtdInsP were paralleled by decreases in PtdIns and PtdInsP₂ (Vivas et al., 2019), confirming broader control of phosphoinositide species by NPC1. Collectively, these data support a link between the lysosome NPC1 protein and regulation of Golgi and Lysosome PtdIns4P levels.

**NPC1 regulates the molecular elements of ER-TGN membrane contact sites**

At ER-TGN and ER-Lysosome MCS, OSBP (Mesmin et al., 2013; Lim et al., 2019), VAPA (Peretti et al., 2008; Lim et al., 2019), and SAC1 (Zewe et al., 2018; Lim et al., 2019) serve as important regulators of PtdIns4P homeostasis (Fig 2A). Thus, we tested if loss of NPC1 function can tune the expression and localization of ER-TGN MCS proteins to potentially account for the changes in subcellular PtdIns4P distribution.

Western blot analysis from U18-treated cells revealed that total cellular protein levels of OSBP were not significantly different from control cells (Fig 2B). Subsequent super-resolution immunofluorescence analysis from tsA201 cells treated with U18 revealed that although cellular protein levels were similar, significantly more OSBP localized to TGN46 regions (Fig 2C and D). Similar results were obtained from NPC1I1061T patient cells (Fig EV1A and B) and U18-treated neurons (Fig 2E and F) compared to appropriate controls. OSBP is recruited to ER-TGN junctions through dual interactions of its PH domain with Golgi PtdIns4P and binding of its FFAT motif to the type II ER membrane protein VAPA (Levine & Munro, 2002; Loewen et al., 2003). With this in mind, we asked if VAPA also accumulates in Golgi regions of cells lacking NPC1. Immunofluorescence analysis determined that, similar to OSBP, VAPA accumulated at the TGN in U18-treated tsA201 cells (Fig 2G and H), at the Golgi of NPC1I1061T patient cells (Fig EV1C and D), and perinuclear regions of NPC1I1061T cells (Fig EV1E and F).

Parallel increases in PtdIns4P (Fig I), OSBP (Fig 2C–F), and VAPA (Fig 2G and H) at ER-TGN MCS have been observed under circumstances of OSBP inhibition (Mesmin et al., 2017). Therefore, we tested if OSBP-mediated PtdIns4P transport kinetics are altered following loss of NPC1 function. To test this hypothesis, we first transfected tsA201 cells with GFP-P4M, to monitor TGN PtdIns4P, and transiently treated cells with a specific inhibitor of PI4KIIβ activity (PIK93 (Toth et al., 2006)). PI4KIIβ is responsible for local PtdIns4P production in the vicinity of OSBP (Mesmin et al., 2017); thus, inhibiting PI4KIIβ, while monitoring P4M intensity at the TGN, allows us to indirectly track the rate of PtdIns4P molecules consumed by OSBP. Transient application of PIK93 caused a rapid and reversible drop in P4M intensity at the Golgi from both control and U18-treated tsA201 cells (Fig EV1G and H). Comparison of vehicle and U18-treated cells revealed that loss of NPC1 function results in both a significantly larger and faster loss of PtdIns4P. This decrease in PtdIns4P biosensor intensity may represent PtdIns4P transferred from the TGN to the ER where it is subsequently degraded by the ER lipid phosphatase SAC1. To more directly measure OSBP kinetics following loss of NPC1 function, we also transfected tsA201 cells with GFP-P4M and treated with a selective OSBP inhibitor (OSW-1 (Burgett et al., 2011)). Time series analysis revealed that loss of OSBP function resulted in faster recruitment of GFP-P4M to the TGN compared to vehicle controls (Fig EV1I and J). Together, these data provide evidence that OSBP-mediated transport of PtdIns4P is accelerated and therefore unlikely to be directly facilitating increases in PtdIns4P following NPC1 loss of function.

Maintenance of the OSBP transfer cycle requires a steep PtdIns4P gradient to be conserved across ER-TGN MCS. This chemical gradient is conserved through the enzymatic actions of SAC1, which degrades its PtdIns4P substrate on ER membranes (Fig 2A). In light of increased TGN PtdIns4P, VAPA, and OSBP levels in cells lacking functional NPC1 (Figs 1 and 2C–H), we asked if SAC1 at ER-TGN MCS is also sensitive to changes in NPC1 function. Measurement of SAC1 protein levels revealed no significant difference between control and NPC1I1061T patient cells (Fig 2I). Overnight inhibition of NPC1 in GFP11-SAC1 cells (endogenous SAC1 tagged with a GFP (Zewe et al., 2018)) caused a significant redistribution of SAC1 to...
Figure 2.
Golgi regions (Fig 2J–K). This result is underscored by immunofluorescence analysis of endogenous SAC1 in NPC1−/−Tg46 patient cells that revealed a similar accumulation of SAC1 at Golgi regions (Fig 2J and K; Appendix Fig S2A–C). SAC1’s precise localization at ER-TGN regions is controversial with some groups offering evidence for SAC1 being localized in ER membranes and acting in cis (Mesmin & Bigay, 2013; Zewe et al., 2018) or trans (Venditti et al., 2019) to dephosphorylate TGN PtdIns4P, while others have proposed SAC1 can traffic to Golgi membranes under different growth conditions to regulate Golgi PtdIns4P levels (Blagoveshchenskaya et al., 2008). Using super-resolution microscopy, we quantified the relative distribution of endogenous SAC1 at the ER and TGN from live vehicle control or U18-treated HEK cells. Appendix Fig S2A–C demonstrates that inhibition of NPC1 leads to an increase in SAC1 at TGN46-positive regions (SAC1TGN46) that occurs in the absence of any changes to SAC1 at SEC61β-positive regions (SAC1SEC61β). To further examine if loss of NPC1 function can alter the gross distribution of ER and TGN, we immunostained GFP11-SEC61 and mCherry-SEC61 and quantified the relative distribution of endogenous SAC1 at the ER and TGN, we next asked if loss of NPC1 function more directly influences PtdIns4P-metabolizing enzymes. Cellular PtdIns4P levels, we next tested the hypothesis that increased recruitment of PI4K enzymes may underlie the elevations in Golgi or Lysosomal PtdIns4P levels following NPC1 inhibition, knockdown, or mutation. To this end, we expressed fluorescently tagged PI4K enzymes and quantified their cellular distribution in NPC1 patient cells, U18-treated tsA201 cells, and neurons. PI4KIIβ and PI4KIIIβ had a similar subcellular distribution across control and U18-treated tsA201 cells (Appendix Fig S3A and B) and thus were excluded from further analysis. In contrast, quantification of overexpressed PI4KIIα and PI4KIIIβ revealed significantly increased levels of both enzymes at perinuclear regions in U18-treated tsA201 cells relative to control (Fig 3C and D). To more precisely determine if these perinuclear increases in enzyme localization reflect increases at the TGN, we fixed control and U18-treated tsA201 cells before staining for endogenous PI4KIIα and PI4KIIIβ levels and TGN46. Super-resolution imaging analysis revealed that the fraction of PI4KIIα (Fig 3E and F) and PI4KIIIβ (Fig 3G and H) overlapping with TGN46 significantly increased following loss of NPC1 function. Similar results were observed with a second more general Golgi marker; Giantin (Appendix Fig S4A–D). These observations were also consistent for neurons (Fig 3I and J), NPC1−/− cells (Appendix Fig S3G–J), and NPC11061T patient fibroblasts (Appendix Figs S3C–F and S4E–L).

Inhibition or disease mutations in NPC1 recruit PI4K enzymes to Golgi and Lysosome membranes

Given that NPC1-mediated changes in VAPA, OSBP, and SAC1 distribution are likely coordinated downstream of increases in PtdIns4P levels, we next asked if loss of NPC1 function more directly influences PtdIns4P-metabolizing enzymes. Cellular PtdIns4P levels are controlled in space and time through the enzymatic activities of the PI4K family of enzymes (PI4KIIα, PI4KIIβ, PI4KIIIα, PI4KIIIβ; Fig 3A). Increases in catalytic activity and/or membrane localization of PI4K lipid enzymes would represent the most intuitive route to increase PtdIns4P levels through the phosphorylation of phosphatidylinositol (PtdIns; Fig 3A). Of the four PI4K family members, PI4KIIα and PI4KIIIβ have been demonstrated to localize to Golgi and lysosome membranes at steady state (Weixel et al., 2005; Sridhar et al., 2013). To assess if a simple increase in the abundance of these PI4K enzymes is responsible for elevated PtdIns4P levels, cell lysates from U18-treated tsA201 cells were immunoblotted for PI4KIIα and PI4KIIIβ (Fig 3B). Western blot analysis determined no changes in the total cellular protein expression of either PI4KIIα or PI4KIIIβ enzymes, suggesting that a simple increase in protein amount is unlikely to account for the elevated TGN and lysosomal PtdIns4P levels.

Next, we tested the hypothesis that increased recruitment of PI4K enzymes may underlie the elevations in Golgi or Lysosome PtdIns4P levels following NPC1 inhibition, knockdown, or mutation. To this end, we expressed fluorescently tagged PI4K enzymes and quantified their cellular distribution in NPC1 patient cells, U18-treated tsA201 cells, and neurons. PI4KIIβ and PI4KIIIβ had a similar subcellular distribution across control and U18-treated tsA201 cells (Appendix Fig S3A and B) and thus were excluded from further analysis. In contrast, quantification of overexpressed PI4KIIα and PI4KIIIβ revealed significantly increased levels of both enzymes at perinuclear regions in U18-treated tsA201 cells relative to control (Fig 3C and D). To more precisely determine if these perinuclear increases in enzyme localization reflect increases at the TGN, we fixed control and U18-treated tsA201 cells before staining for endogenous PI4KIIα and PI4KIIIβ levels and TGN46. Super-resolution imaging analysis revealed that the fraction of PI4KIIα (Fig 3E and F) and PI4KIIIβ (Fig 3G and H) overlapping with TGN46 significantly increased following loss of NPC1 function. Similar results were observed with a second more general Golgi marker; Giantin (Appendix Fig S4A–D). These observations were also consistent for neurons (Fig 3I and J), NPC1−/− cells (Appendix Fig S3G–J), and NPC11061T patient fibroblasts (Appendix Figs S3C–F and S4E–L).

In addition to increased PI4KIIα and PI4KIIIβ levels at Golgi membranes, we also observed that fluorescently tagged PI4KIIα and PI4KIIIβ preferentially localized to endolysosomal locations in NPC11061T patient cells (Fig EV2A–D). This distribution is consistent with increased lysosomal PtdIns4P observed following loss of

---

**Figure 3.** PI4KIIα and PI4KIIIβ are recruited to Golgi and lysosome membranes in NPC1 disease.

A. Diagram showing PtdIns4P metabolizing enzymes.

B. Representative Western blot for PI4KIIα and PI4KIIIβ in control and U18-treated tsA201 cells. Protein levels were normalized to β-actin. Individual points (PI4KIIα: n = 3; PI4KIIIβ: n = 4) represent protein levels of each +U18 band normalized to control.

C. Left: Confocal images of control (left) and U18-treated (right) tsA201 cells expressing PI4KIIα-GFP. Bottom panels show an enlarged view of the probe centered on a perinuclear region. Right: Quantification of perinuclear PI4KIIα intensity relative to the cytoplasm. Control: n = 12; U18: n = 14.

D. Same as (C) only PI4KIIIβ. Control: n = 12; U18: n = 15.

E. Confocal images of control and U18-treated tsA201 cells fixed and stained for PI4KIIα (left), TGN46 (middle), and merge (right). Black rectangles show expanded views of PI4KIIα and TGN46 regions.

F. Quantification of PI4KIIα signal in TGN46 regions (PI4KIIαTGN46). Control: n = 36; U18: n = 36.

G, H. Same as (F, E) only stained with PI4KIIIβ. Control: n = 35; U18: n = 43.


Data information: Data are all expressed as mean ± SEM from individual cells, and all statistical analyses were conducted using unpaired t-test with ***P < 0.001, ****P < 0.0001. Source data are available online for this figure.
Figure 3.
NPC1 function (Fig 1H–J). In line with the concept that PI4KIIα and PI4KIIβ are responsible for elevations in lysosomal PtdIns4P in NPC1 disease, endogenous levels of both enzymes were significantly elevated at LAMP1-positive membranes (Fig EV2E–H). These data suggest a NPC1-dependent mechanism, conserved across multiple cell types, for the recruitment of PI4KIIα and PI4KIIβ to Golgi and lysosome membranes.

**DHHC3-dependent recruitment of PI4KIIα underlies NPC1-dependent increases in Golgi PtdIns4P**

Localization of PI4K isoforms can be influenced by a number of factors including palmitoylation (Lu et al., 2012), phosphorylation (Hauser et al., 2005), and protein interactions (Haynes et al., 2005; Sasaki et al., 2012; Greninger et al., 2013; Chalupska et al., 2019). For PI4KIIα, the lipid kinase activity, Golgi localization, and membrane binding are dependent on the palmitoylation of a cysteine-rich motif by DHHC3 and DHHC7 palmitoyl transferases (Asp-His-His-Cys; DHHC; (Fig 4A)) (Lu et al., 2012). To confirm a central role for PI4KIIα in increasing subcellular PtdIns4P levels following NPC1 loss of function, we first decided to knockdown PI4KIIα levels. To this end, we transfected Cas9-expressing HEK293 cells for 48 h with sgPI4KIIα and a fluorescent transfection marker. Western blot analysis revealed that total PI4KIIα protein levels were reduced by ~75%, a reduction mirrored by immunofluorescence analysis from randomized regions of interest (Fig EV3A and B). A targeted analysis of only those cells transfected with a fluorescent marker revealed a significantly larger, ~90% reduction in immunofluorescence signal at Golgi regions (Fig EV3C). Based on these analyses, all subsequent quantifications were performed on cells positive for a transfection marker.

To test if reducing PI4KIIα protein levels affected NPC1-dependent increases in PtdIns4P, we quantified the cellular distribution of P4M-YFP (Fig 4B and C). Comparing control, U18-treated, and U18-treated PI4KIIα knockdown (“sgPI4KIIα”) cells revealed that sgPI4KIIα significantly reduced steady-state and U18-dependent increases in Golgi PtdIns4P (Fig 4B and C). To establish a role for DHHC3 in recruiting PI4KIIα to the Golgi, we quantified the distribution of endogenous DHHC3 in control and NPC1<sup>1061T</sup> patient fibroblasts. Analysis of immunofluorescence images revealed NPC1<sup>1061T</sup> fibroblasts had significantly elevated DHHC3 at Golgi regions (Fig 4D and E). In contrast to endogenous DHHC3, the expression of HA-DHHC7 was not significantly different between control and NPC1<sup>1061T</sup> patient cells (Fig EV3D) and was not further investigated. These data suggest that an increase in PI4KIIα palmitoylation may underlie increases in PtdIns4P following loss of NPC1 function. To test this hypothesis further, we overexpressed DHHC3 in control fibroblasts to determine if simply increasing DHHC3 levels resulted in changes to P4M and PI4KIIα at Golgi membranes. Quantitative analyses revealed that overexpressing DHHC3 in control cells resulted in an increase in both P4M (Fig 4F and G) and PI4KIIα (Fig 4H and I), but not PI4KIIβ, at Golgi membranes to a similar range as NPC1 cells. Thus, transiently overexpressing DHHC3 increases Golgi PtdIns4P to a similar level as NPC1 loss of function cells. To further test a role for DHHC3 in recruiting PI4KIIα to Golgi membranes, we knocked down DHHC3 by ~90% (“sgDHHC3”; Fig EV3E) using CRISPR-Cas9 editing and found that reducing DHHC3 levels in NPC1 loss of function cells normalized PtdIns4P back into a control range (Fig 4J; analysis Fig 4C). To rule out off-target effects of CRISPR editing or alterations in Golgi integrity due to DHHC3 knockdown, we expressed a dominant-negative DHHC3<sup>Δ1575</sup> plasmid (DN-DHHC3 (Lu et al., 2012)), that lacks the
ability to palmitoylate PI4KI\(\alpha\) in TGN membranes (Lu et al., 2012), and analyzed P4M and PI4KI\(\alpha\) distribution in control and NPC1\(^{I1061T}\) cells. Similar to DHHC3 knockdown, expression of DN-DHHC3 and analyzed P4M and PI4K \(\alpha\) in NPC1\(^{I1061T}\) fibroblasts significantly reduced Golgi P4M (Fig 4K and L) and PI4K \(\alpha\) (Fig EV3F) back to control levels. Thus, DHHC3-dependent recruitment of PI4KI\(\alpha\) appears to be part of the mechanism that increases Golgi PtdIns4P in NPC1 disease.

Ordinarily, PI4KI\(\alpha\) is fully palmitoylated and behaves almost entirely as an integral membrane protein (Barylko et al., 2009). Thus, the increase in PI4KI\(\alpha\) observed in NPC1 fibroblasts, or control cells overexpressing DHHC3, likely occurs due to a parallel reduction in PI4KI\(\alpha\) from a different membrane compartment(s). To begin testing this hypothesis, we fixed and stained control and NPC1\(^{I1061T}\) patient fibroblasts for endogenous PI4KI\(\alpha\) and markers of early endosomes (EEA1) and late endosomes (RAB7). Quantification of the subcellular localization between PI4KI\(\alpha\) and markers showed no clear differences between control and NPC1\(^{I1061T}\) cells, with a slightly reduced area of overall overlap between signals (Fig EV4A–C). Contrary to this modest finding, analysis of PI4KI\(\alpha\) and EEA1 determined a 50% reduction in both the area of overlap and the intensity of signal from NPC1\(^{I1061T}\) cells relative to control (Fig EV4D–F). Therefore, at least one subcellular compartment loses a significant amount of PI4KI\(\alpha\) following loss of NPC1 function, that we suggest is recruited to Golgi via DHHC3. Future experiments are needed to fully dissect the molecular mechanism(s) underlying loss of PI4KI\(\alpha\) from early endosomes and subsequent increase at TGN membranes.
Finally, the increased localization of endogenous PI4KIIα to LAMP1-positive structures in NPC1 cells (Fig EV2E and F) prompted us to ask if DHHC3 localization was also increased at these membranes. To address this question, we fixed control and NPC1I1061T patient cells and quantified the distribution of DHHC3 on LAMP1-positive membranes. Similar to Golgi membranes, the intensity of DHHC3 was significantly increased on lysosomes from NPC1I1061T cells relative to control (Fig EV4G–I). To confirm a functional role for DHHC3 in regulating increases in lysosomal PtdIns4P in NPC1 disease, we treated HEK293-Cas9 cells with sgDHHC3 and compared the distribution of P4M relative to control cells. Consistent with DHHC3-dependent palmitoylation of PI4KIIβ, increasing PtdIns4P on lysosomal membranes in NPC1 disease, knockdown of lysosomal DHHC3 (Fig EV4J) in NPC1I1061T cells or HEK293-Cas9 cells normalized lysosomal P4M signals back to control levels (Fig 4M and N).

Collectively, these data provide evidence that loss of NPC1 function initiates a signaling cascade that results in the recruitment of PI4KIIβ to Golgi and lysosome membranes, via DHHC3-dependent palmitoylation, to increase PtdIns4P levels.

**ACBD3-mediated recruitment of PI4KIIβ to Golgi and lysosomes increases PtdIns4P levels in NPC1 disease**

Having established a role for DHHC3-PI4KIIβ increasing Golgi and lysosomal PtdIns4P levels in NPC1 disease, we next investigated the mechanism underlying increased recruitment and/or activity of PI4KIIβ to Golgi and endolysosomal membranes following NPC1 loss of function. To begin, we asked if PKD-mediated phosphorylation of PI4KIIβ underlies the U18-dependent increase in Golgi PtdIns4P levels. PKD has a number of Golgi substrates, with its recruitment linked to the stimulation of PI4KIIβ lipid kinase activity (Hausser et al., 2005) and OSBP localization (Nhek et al., 2010). Despite strong rationale for its potential involvement, inhibition of PKD activity failed to abrogate the U18-dependent increase in Golgi PtdIns4P levels (Appendix Fig SSA and B).

PI4KIIβ is a soluble lipid kinase that can interact with a number of different proteins, including the multi-functional adaptor protein, Acyl-CoA-binding domain-containing 3 (ACBD3; Fig 5A) (Sasaki et al., 2012; Greninger et al., 2013; Chalupská et al., 2019). Therefore, we tested if ACBD3 is involved in increasing PI4KIIβ levels at Golgi and endolysosome membranes. To begin, we quantified ACBD3 protein levels from control and NPC1I1061T patient cells via Western blot and found cellular ACBD3 protein levels were significantly increased in NPC1 disease cells (Fig 5B). Subsequent immunofluorescence analyses of ACBD3 revealed a general pattern consistent with its reported localization at Golgi (Greninger et al., 2012; Sasaki et al., 2012) and lysosome membranes (White et al., 2016) (Fig 5C), with NPC1I1061T patient cells having significantly elevated levels of ACBD3 at Golgi (Fig 5C and D) and endolysosomal regions compared to control (Appendix Fig S5C and D). To test whether increasing ACBD3 expression in control cells alters PtdIns4P and PI4KIIβ to similar levels as NPC1 loss-of-function cells, we overexpressed GFP-ACBD3 and quantified Golgi P4M, PI4KIIα, and PI4KIIβ. Consistent with a role for ACBD3 in mediating the increases in PtdIns4P observed in NPC1 loss-of-function cells, overexpressing GFP-ACBD3 in control cells increased P4M (Fig 5E and F) and PI4KIIβ (Fig 5G and H), but not PI4KIIα, at Golgi membranes. Therefore, like DHHC3, increasing ACBD3 expression in control cells increases P4M and PI4KIIβ to similar levels as NPC1 loss-of-function cells. To further probe the hypothesis that loss of NPC1 function drives ACBD3-dependent recruitment of PI4KIIβ to elevate Golgi and endolysosome PtdIns4P levels, we knocked down ACBD3 (“sgACBD3”) and quantified Golgi and lysosomal PtdIns4P levels. As before, treating HEK293-Cas9 cells expressing P4M-YFP with U18 increased Golgi and lysosome PtdIns4P levels (Fig 5I and J). Knocking down PI4KIIβ (“sgPI4KIIβ”; ~ 90% Fig EV3C) or ACBD3 (“sgACBD3”; ~ 65% Fig EV3A and Appendix Fig S5E and F) resulted not only in reduced steady-state PtdIns4P levels, but also significantly reduced U18-mediated elevations in Golgi and lysosomal PtdIns4P (Fig 5I and J; Appendix Fig S5G). Interestingly, Golgi PtdIns4P was refractory to U18-treatment when PI4KIIα and PI4KIIβ were both knocked down (Fig 5J). We take this to mean that both PI4K enzymes not only regulate basal Golgi PtdIns4P levels, but also play important roles in mediating increases in Golgi PtdIns4P following loss of NPC function. While the underlying molecular elements of this signaling pathway may be more complex, we believe that collectively our data present a model where NPC1-dependent increases in ACBD3 protein levels at Golgi and lysosome membranes enhance recruitment of PI4KIIβ to increase PtdIns4P synthesis.

**Knocking down ACBD3 in NPC1I1061T patient cells rescues cellular PtdIns4P phenotypes and prevents recruitment of mTORC1**

A major cellular consequence of disease mutations in NPC1 is OSBP-mediated accumulation of cholesterol on the cytoplasmic leaflet of lysosome membrane which drives the recruitment of the master regulator of growth signaling, mTORC1, resulting in aberrant growth signaling (Lim et al., 2019). Under this model proposed by the Zoncu group, a key factor initiating OSBP-mediated cholesterol transfer and mTORC1 recruitment is the presence of lysosomal PtdIns4P which binds to OSBP’s PH domain to tether ER-lysosome MCS. To date, there are no reports identifying the phosphoinositide metabolism elements required for cholesterol-dependent mTORC1 recruitment in NPC1 disease. With this in mind, we transfected patient cells with Cas9- and sgRNAs-directed against ACBD3, PI4KIIα, or PI4KIIβ, while simultaneously monitoring cellular PtdIns4P levels with the P4M biosensor. In NPC1I1061T patient cells, individual knockdown of either PI4KIIα or PI4KIIβ significantly reduced both Golgi and lysosomal PtdIns4P levels (Fig 6A and B). It should be noted that sgPI4KIIβ was more efficient at reducing Golgi PtdIns4P than sgPI4KIIα in NPC1I1061T cells, suggesting a more prevalent role in maintaining Golgi PtdIns4P. This concept is further supported by immunofluorescence data that demonstrated a larger fold change in ACBD3 levels (Appendix Fig S5C and D), compared to DHHC3 (Fig EV4G–I), at lysosome membranes of NPC1I1061T cells relative to control.

To test if ACBD3 is necessary for increased lysosomal PtdIns4P generation in NPC1 disease, we transfected sgACBD3 into NPC1I1061T patient cells along with Cas9 and P4M-YFP. Similar to HEK293-Cas9 cells treated with U18 (Fig 5I and J), transfecting sgACBD3 into NPC1I1061T rescued PtdIns4P at Golgi regions levels back to control ranges and significantly reduced endolysosomal PtdIns4P levels (Fig 6A and B). To test if increases in lysosomal PtdIns4P production drives mTORC1 recruitment under NPC disease conditions, we transfected Cas9 and sgACBD3 into NPC1I1061T patient cells and fixed and stained for endogenous mTORC1. Similar
Figure 5. ACBD3-mediated PI4KIIβ recruitment contributes to increased PtdIns4P levels at Golgi membranes following loss of NPC1 function.

A. Diagram illustrating the Golgi recruitment mechanisms of PI4KIIβ.
B. Representative Western blot for ACBD3 in control and NPC11061T patient fibroblasts. Protein levels were normalized to β-actin. Control: n = 26; NPC11061T: n = 27. A paired t-test was used for the statistical analysis with *P < 0.05.
C. Confocal images of control and NPC11061T patient fibroblasts immunolabeled for ACBD3. Black and orange squares show expanded views of anti-ACBD3 in Golgi and endomembrane compartments, respectively.
D. Analyses of ACBD3 intensity distributed in Golgi (left graph; Control: n = 9; NPC11061T: n = 9) or in endomembranes (right graph; Control: n = 1,360; NPC11061T: n = 1,645 from 15 cells), normalized to the cytoplasm.
E. Confocal images of control (1st column) and NPC11061T fibroblasts (2nd column) expressing mCherry-P4M or control fibroblasts expressing PAM-mCherry and GFP-ACBD3 (3rd and 4th columns).
F. Quantification of PI4KIIβ-P4M intensity relative to cytoplasm. Control: n = 11; NPC11061T: n = 14; Control + ACBD3: n = 12
G. Confocal micrographs from control or GFP-ACBD3 expressing tsA201 cells fixed and stained for PI4KIIβ or PI4KIIIβ. Bottom panels show enlarged views of ACBD3, PI4KIIβ, or PI4KIIIβ at Golgi regions.
H. Quantification of PI4KIIβ (left; control: n = 42; ACBD3: n = 28), or PI4KIIIβ (right; control: n = 39; ACBD3: n = 20) intensity relative to cytoplasm.
I. Confocal images of control and sgACBD3 HEK293-CAS9 cells expressing PAM-YFP, treated with or without U18. Bottom panels show enlarged views of PtdIns4P in Golgi and in endomembrane compartments.
J. Quantitative analyses of P4M-YFP mean fluorescence intensity at Golgi (left graph) or endomembranes (right graph) normalized to the cytoplasm. * represents a significant difference (P < 0.05) between control and other non-U18 treated groups; # represents a significant difference (P < 0.05) between U18 treated and other U18 treated sgRNA groups. For left graph: Control: n = 19; U18: n = 13; sgPI4KIIβ: n = 12; sgPI4KIIβ + U18: n = 11; sgPI4KIIβ + U18: n = 12; sgPI4KIIIβ + U18: n = 12; sgPI4KIIβ + sgPI4KIIIβ + U18: n = 12; sgACBD3: n = 15; sgACBD3 + U18: n = 16. For right graph: control: n = 149; U18: n = 251; sgACBD3: n = 138; sgACBD3 + U18: n = 190. Please note that “control” and “U18” datasets in Fig 5J are identical to those in Fig 4C. Data for all CRISPR experiments were collected on the same days.

Data information: All the data are expressed as mean ± SEM from individual cells with the exception of (D, right) and (I, right) which represents values from individual subcellular structures, n = 10 cells and n = 13 cells, respectively. Statistical analyses include unpaired t-test (D left graph, H left graph, Mann-Whitney test (D right graph, H right graph), or one-way ANOVA (F). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. As determined by a Grubbs’ test, with an alpha value of 0.05 (see methods), significant outliers were excluded from (I, right). Source data are available online for this figure.
to previous reports (Lim et al., 2019), NPC1<sup>1061T</sup> disease mutations result in increased steady-state accumulation of mTORC1 at lysosome membranes (Fig 6C). Knocking down ACBD3 in NPC1<sup>1061T</sup> cells significantly reduced lysosomal mTORC1 recruitment back into some membranes (Fig 6C). Knocking down ACBD3 in NPC1<sup>1061T</sup> patient fibroblasts result in increased steady-state accumulation of mTORC1 at lyso-

**NPC1-dependent alterations in PI4K distribution are mediated via the SREBP pathway**

The data presented thus far provide evidence linking loss of NPC1 function to the DHHC3- and ACBD3-mediated recruitment of PI4K enzymes to the TGN. The question remains, what is upstream of these recruiting factors that mechanistically links loss of NPC1 activity to recruitment of PI4K enzymes and increases in Golgi PtdIns4P? The major role of NPC1 is to facilitate the egress of cholesterol from luminal to cytoplasmic leaflets of the lysosomal membrane bilayer. Transported lysosomal cholesterol then serves as a signaling

---

**Figure 6. PtdIns4P produced by PI4KIIß regulates mTORC1 recruitment to endomembrane compartments.**

A Confocal images of control, NPC1<sup>1061T</sup> and ACBD3-deleted NPC1<sup>1061T</sup> patient fibroblasts expressing P4M-YFP. Black and orange squares show expanded views of PtdIns4P in Golgi and endo/lysosomal compartments, respectively.

B Top graph: analysis of Golgi P4M-YFP intensity normalized to the cytoplasm in control and NPC1<sup>1061T</sup> patient fibroblasts and NPC1<sup>1061T</sup> fibroblasts lacking either ACBD3 (sgACBD3), PI4KIIIß (sgPI4KIIIß) or PI4KIIß (sgPI4KIIß). Control: n = 9, NPC1<sup>1061T</sup>; n = 12, NPC1<sup>1061T</sup> + sgACBD3: n = 9, NPC1<sup>1061T</sup> + sgPI4KIIIß: n = 8. Bottom graph: analysis of P4M-YFP intensity in endomembrane compartments normalized to the cytoplasm in NPC1<sup>1061T</sup> patient fibroblasts. NPC1<sup>1061T</sup>, n = 40; NPC1<sup>1061T</sup> + sgACBD3: n = 172.

C Confocal images of control, NPC1<sup>1061T</sup> and ACBD3-deleted NPC1<sup>1061T</sup> patient fibroblasts immunolabeled with mTORC1 antibody. Bottom images show expanded views of mTORC1 immunolabeling in the regions indicated by the dashed squares in the main images. White dashed lines represent the outline of each cell.

D Quantification of mTORC1 mean integrated density normalized by cell area in control, NPC1<sup>1061T</sup> and ACBD3-deleted NPC1<sup>1061T</sup> patient fibroblasts. Control: n = 15; NPC1<sup>1061T</sup>, n = 14; NPC1<sup>1061T</sup> + sgACBD3: n = 11.

Data information: All the data are expressed as mean ± SEM from individual cells with the exception of (B, bottom) which represents values from individual subcellular structures. Statistical analyses include one-way ANOVA (A, top), Mann–Whitney test (B, bottom), and one-way ANOVA (D). *P < 0.05; **P < 0.01; ***P < 0.001. Source data are available online for this figure.
molecule (Castellano et al., 2017; Lim et al., 2019) that can be indirectly transported to the plasma membrane (Infante & Radhakrishnan, 2017) or directly transferred to the ER at ER-lysosome MCS (Rocha et al., 2007; Vihervaara et al., 2011). Levels of ER cholesterol are precisely monitored by a family of transcription factors called Sterol Regulator Element Binding proteins (SREBPs). Under conditions of reduced ER cholesterol levels, SREBPs are proteolytically cleaved and subsequently translocate to the nucleus where they upregulate the synthesis of many proteins (Brown & Goldstein, 1997; Rome et al., 2008). The general findings that de novo cholesterol synthesis, LDL uptake, and increased SREBP activity in NPCI1061T patient cells have been established (Pentchev et al., 1985; Liscum & Faust, 1987; Frolov et al., 2003), therefore, we wanted to test the hypothesis that SREBP activation was upstream of PI4K recruitment to the Golgi.

To begin, we wanted to determine if SREBP impacts the transcription of DHHC3, ACBD3, PI4KIIa, and PI4KIIIb. qPCR analysis of mRNA levels revealed that DHHC3 and ACBD3 levels were elevated in NPC11061T cells relative to control (Fig 7A), whereas PI4K levels were unchanged. Treating NPC11061T cells overnight with the specific SREBP site 1 protease inhibitor, PF-429242 (PF), normalized transcript levels back into control ranges. These data are in line with previously published microarray analysis detailing that ACBD3 is a target gene for SREBP (Rome et al., 2008) and suggest that SREBP may be responsible for the enhanced recruitment of PI4K enzymes to the Golgi following loss of NPC1 function. To test this idea, we overexpressed fluorescently tagged PI4Ks in tsA201 cells and monitored their distribution under conditions of altered NPC1 or SREBP function. Quantitative analysis of PI4KIIa distribution in cells treated concurrently with U18 and PF-429242 revealed identical levels of PI4KIIa at Golgi regions compared to vehicle-treated control cells (Fig 7B and C). Similar analysis performed on GFP-PI4KIIIb expressing cells revealed that PI4KIIIb recruitment to Golgi membrane was also refractory to U18 when treated concurrently with PF-429242 (Fig 7D and E). Parallel experiments investigating PtdIns4P metabolism revealed that U18-mediated increases in P4M intensity were also sensitive to SREBP pathway inhibition (Fig 7F and G).

To provide further evidence for SREBP’s role in facilitating PI4K recruitment, we generated two additional datasets using overexpressed SREBP and cells lacking functional SREBP. Overexpressing SREBP increases the fractional amount of active, nuclear-localized SREBP and as such provides a way to activate SREBP, independently of NPC1. Similar to U18-treated or NPC1 disease mutations, cells overexpressing SREBP also had significantly elevated PI4KIIa and PI4KIIIb at Golgi regions (Appendix Fig S6A–D). To further support a role for SREBP in mediating PI4K recruitment, we analyzed the distribution of P4M in control cells relative to SCAP−/− cells, that are unable to escort SREBP to the Golgi for processing to its “active” nuclear form (Rawson et al., 1999). Consistent with SREBP’s involvement in mediating increases in Golgi and endomembrane PtdIns4P levels, P4M distribution in SCAP−/− cells was similar to control (Fig 7H and I and Appendix Fig S6E and F). It should also be noted that the distribution of SAC1 at the Golgi mirrored changes in Golgi PtdIns4P levels (Appendix Fig S7), likely ensuring the faithful maintenance of a steep PtdIns4P gradient for cholesterol transport. These independent datasets provide preliminary evidence that activation of SREBP maybe upstream of recruitment of PI4KIIa and PI4KIIIb to Golgi and endolysosomal regions.

**NPC1-mediated elevations in Golgi PtdIns4P increase Golgi to PM trafficking**

We have identified a novel signaling axis that links NPC1-mediated cholesterol efflux to tuning of molecular contents of ER-TGN MCS. A key remaining question is with regard to the functional consequence of aberrant Golgi PtdIns4P in NPC disease. Golgi PtdIns4P plays a crucial role in the spatial and temporal recruitment of adaptor proteins to facilitate anterograde trafficking of cargo proteins destined for endosomes and the PM. While acute depletion of PtdIns4P prevents the exit of cargo from the Golgi destined for the PM, increased Golgi PtdIns4P leads to a malignant secretory phenotype in cancer (reviewed Waugh (2019)). To dissect a role for NPC1 in regulating secretory traffic, we first measured the distribution of cation-independent mannose 6-phosphate receptors (CI-MPR). These receptors are dynamically trafficked between the TGN and endosomes, as well as the PM and as such give a broad overview of secretory trafficking patterns (Dong et al., 2016). Control and NPC11061T patient cells were incubated with anti-CI-MPR (binds the extracellular region of CI-MPR at the PM) for 1 h, and the intracellular distribution of CI-M6PR antibody was detected by immunofluorescence. Quantitative analysis of the resulting confocal micrographs revealed that the CI-M6PR antibody was internalized with the receptor and accumulated at Giantin-positive Golgi membranes in control patient cells (Fig 8A, left middle row), as well as other non-giantin-positive internal membranes that likely correspond to endosomes (Fig 8A, left bottom row; Fig EV5A and B). In contrast, NPC11061T patient cells had a significantly higher accumulation of CI-MPR fluorescence at the Golgi (Fig 8A, right panel), coupled with decreased levels of fluorescence at peripheral vesicles (Fig 8A, right panel; Fig 8B for analysis). Thus, trafficking patterns are altered following loss of NPC1 function.
Figure 7.
To more specifically test if NPC1 loss of function can alter Golgi trafficking/sorting, we quantified the cellular distribution of the small GTPase ARF1. ARF1 has a well-established role in the assembly and budding of COPI vesicles at the Golgi, where its active form recruits coatomer for the formation of COPI-coated vesicles (Serafini et al., 1991; Palmer et al., 1993). With this in mind, analysis of expression patterns of ARF1-GFP revealed significantly greater accumulation at Golgi regions of NPC1<sup>1061T</sup> cells relative to control (Fig 8C and D). In addition, we also noticed more ARF1-positive tubular structures protruding from the Golgi region (Fig 8C, black arrows). These ARF1 tubules have previously been suggested to represent the major membrane flow out of the Golgi, with approximately one-third required to maintain plasma membrane growth (Bottanelli et al., 2017). These data, combined with increases in Golgi PtdIns4P (Fig 1), indicate that Golgi secretions may be accelerated following loss of NPC1 function.

To analyze and quantify transport characteristics in cells lacking functional NPC1, we utilized the retention using hooks (RUSH) assay (Boncompain et al., 2012). The RUSH system is based on the reversible interaction of a “hook” protein fused to streptavidin (Str) and stably anchored in a donor compartment with a reporter protein of interest fused to streptavidin-binding peptide (SBP). The addition of Biotin facilitates the release of the reporter from the organelle-localized hook and triggers the secretion of a fluorochrome protein to the reporter protein allows for tracking and quantification of secretion rates between different organelles. Using the RUSH system, we retained cargo (tumor necrosis factor α (TNFα); TNF-SBP-mCherry), destined for the PM, in the ER (Str-KDEL) and analyzed the transport kinetics following the addition of Biotin (Fig 8E and F). Experiments performed at 37°C showed that TNFx-SBP-mCherry was initially retained in the ER (t = 0 s) through the interactions with Str-KDEL. Addition of Biotin facilitated the release of the reporter and its subsequent trafficking to Golgi apparatus within 15 min (Fig 8E and F; “control”, black trace), before reaching the PM within ~25 min. Time series analysis of Golgi regions of interest from control cells revealed that the rate of TNFx-SBP-mCherry accumulation had a time constant of approximately 454 s (Fig 8G, bottom, Tau<sub>arrive</sub> Golgi), an interval between 50% increase in intensity and 50% decrease in intensity (50:50 duration) of 1,200 s, and a rate of anterograde secretion to proximal membranes of approximately 1,548 s (Tau<sub>leave</sub>). In contrast, cells treated overnight with U18, to inhibit NPC1 function, had significantly altered trafficking kinetics with the average time constant of Golgi accumulation (U18: Tau<sub>arrive</sub> = 205 s), 50:50 duration (U18: 780 s), and secretion rate from the Golgi (U18: Tau<sub>leave</sub> = 294 s) all significantly faster (Fig 8E-G; red images, lines, and histograms). In addition, we analyzed TNFx-SBP-mCherry intensity from ER regions of interest and determined that the overall rate of secretion from the ER is similar between control and U18-treated, with a key difference being that cargo is released sooner from U18-treated cells (Fig EV5C).

To understand how NPC1-dependent changes in trafficking may influence anterograde secretion toward the PM, we conducted similar experiments using TIRF microscopy (Fig 8H and I). In resting control cells, TNFx-SBP-mCherry was visualized within the TIRF footprint as discrete puncta, likely representing regions of close opposition between the ER and PM. Upon the addition of Biotin, there was an initial loss of intensity within the TIRF evanescent field which represents the cargo exiting the ER and trafficking to the Golgi (Fig 8H, black “control”). Within as little as 1,000 s, individual puncta, which we suggest are secretory vesicles fusing with the PM, reappeared within the TIRF field of view and were accompanied by a concurrent increase in intensity within a ROI encompassing the entire TIRF footprint. Analysis from control cells revealed the TIRF footprint intensity increased 2.5-fold with an average time constant 863 s (Fig 8H-J). Comparing control to U18-treated cells revealed that secretion of TNFx-SBP-mCherry from the ER to the PM was significantly faster (U18: Tau<sub>arrive</sub> = 404 s), with more cargo trafficked to the PM per unit time (5.2-fold change; Fig 8I and J; red “+U18”). Similar U18-dependent increases in trafficking kinetics were observed with a VSVG plasmid that was released directly from the Golgi (Fig EV5D). Next, we tested a role for DHHC3 and ACBD3 in mediating U18-dependent increases in

Figure 8. SREBP inhibition alleviates vesicular trafficking defects in NPC1 disease.

A Confocal images of control and NPC1<sup>1061T</sup> patient fibroblasts immunolabeled for Giantin and CI-M6PR. Insets show expanded views of each immunolabeling in the Golgi region (upper insets) or centered on endomembranes (bottom inset, merged signals). Dashed gray and white lines represent the outline of each cell.

B Analysis of the mean area of M6P and Giantin colocalizing puncta (top graph; Control: n = 23; NPC1<sup>1061T</sup>; n = 18) and of their mean fluorescence intensity (bottom graph; Control: n = 18, NPC1<sup>1061T</sup>; n = 18) in control and NPC1<sup>1061T</sup> patient fibroblasts.

C Confocal images of control and NPC1<sup>1061T</sup> patient fibroblasts expressing ARF1-GFP. Insets show enlarged views of ARF1 in the Golgi area. Tubular structures were observed in NPC1<sup>1061T</sup> patient fibroblasts as indicated by the black arrows.

D Quantification of ARF1 fluorescence intensity in Golgi normalized to the cytoplasm in control and NPC1<sup>1061T</sup> patient fibroblasts: Control: n = 10, NPC1<sup>1061T</sup>; n = 11.

E Live confocal images of control and U18-treated cells transfected with Str-KDEL-TNF-SBP-mCherry. Images are taken at the indicated time points after biotin addition (at time 0 s) and the corresponding distribution of the TNFx-SBP-mCherry within the cell is illustrated in the upper row.

F Average time course of mean TNFx-SBP-mCherry fluorescence intensity in Golgi normalized to the initial fluorescence value. Shaded area represents the SEM. Control: n = 11; U18: n = 15.

G Analysis of the time constants for TNFx-SBP-mCherry to reach and leave the Golgi (Tau<sub>arrive</sub> and Tau<sub>leave</sub>, respectively) and the full duration at half maximum (50:50 Duration), calculated from the upper traces. Error bars represent SEM. Control: n = 11; U18: n = 13-15.

H Same as (E) except images are TIRF footprints of tsA201 cells treated either with vehicle (control) or with U18.

I Averaged time course of the mean plasma membrane fluorescence intensity normalized to the initial fluorescence value in tsA201 cells treated either with vehicle (control), with U18 alone, or together with PF. Shaded area represents the SEM, n = 9.

J Quantitative analysis of the time constants for TNFx-SBP-mCherry to reach the plasma membrane (Tau<sub>arrive</sub> PM) and the maximal change in fluorescence intensity relative to the initial fluorescence value (Intensity Change TIRF F/F<sub>0</sub>). Error bars represent SEM. Control: n = 6-9; U18: n = 8-9; U18+PF: n = 5-9.

Data information: All the data are expressed as mean ± SEM from individual cells, and all statistical analyses were conducted using unpaired t-test with *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001. Source data are available online for this figure.
Figure 8.
Golgi secretion. To begin, we overexpressed DHHC3 and/or ACBD3 and found that while their individual expression increased trafficking rates to the PM, it was their dual expression that increased trafficking rates to the same extent as U18 (Fig EV5E). Conversely, knocking down either DHHC3 or ACBD3 abrogated U18-dependent increases in TNFα-SBP-mCherry secretion (Fig EV5F). Finally, we tested the involvement of the SREBP pathway in facilitating the increases in trafficking observed with U18 treatment. Consistent with its ability to regulate PI4K and PtdIns4P levels at the Golgi (Fig 7), SREBP overexpression accelerated secretion (Fig EV5G), while cells treated with a SREBP inhibitor were refractory to changes by U18 (Fig 8I and J; blue line) with the rate of traffic to the PM (PF: T_{\text{tau,(int)}} = 720 s) and overall amount (2.9-fold change) of cargo delivered not statistically different from control. Collectively, these data support a role for NPC1 in tuning Golgi secretion through SREBP-dependent control of Golgi PtdIns4P.

**Discussion**

We have identified a novel signaling axis that connects NPC1 cholesterol efflux to the regulation of Golgi and lysosomal PtdIns4P levels (Appendix Fig S8). The molecular steps linking changes in the functional status of NPC1 to alterations in membrane PtdIns4P levels appear to involve cholesterol-dependent transcriptional changes in the recruitment machinery of PI4K metabolizing enzymes. Specifically, we have discovered that loss of NPC1 function increases DHHC3 and ACBD3 levels to enhance recruitment of PI4KIIα and PI4KIIβ at Golgi and lysosomes, leading to elevations in membrane PtdIns4P. Crucially, we demonstrate this signaling node is conserved across multiple cell types, including patient cells and mouse neurons harboring the most prevalent NPC disease mutation. The importance of this signaling pathway in health and NPC disease is underscored by experiments demonstrating that loss of NPC1 function causes aberrant increases in anterograde trafficking and recruitment of the master growth regulator mTORC1 at the Golgi and lysosome membranes, respectively. Thus, NPC1 is a crucial rheostat capable of tuning cellular growth and rate of delivery of proteins to cellular membranes.

At the core of our findings is the recruitment of PI4KIIα and PI4KIIβ to both Golgi and lysosome membranes following loss of NPC1 function. The presence of these PI4K enzymes at Golgi and lysosome membranes has been independently reported by multiple groups (Wong et al., 1997; Wei et al., 2002; Guo et al., 2003; Wang et al., 2003; Waugh et al., 2003). For PI4KIIα, significant evidence suggests a key role for palmitoylation-dependent recruitment to Golgi membranes by palmitoyl acyltransferases, such as DHHC3/7 (Lu et al., 2012). Our evidence for the involvement of DHHC3 in recruiting PI4KIIα to increase Golgi PtdIns4P is (i) DHHC3 enrichment at Golgi membranes, (ii) overexpression of DHHC3 increases PI4KIIα and PtdIns4P levels at Golgi membranes, (iii) knockdown of DHHC3 reduces Golgi PtdIns4P levels in NPC1 cells, and (iv) overexpression of a dominant-negative protein that lacks the ability to palmitoylate PI4KIIα, reduces PI4KIIα recruitment and elevations in PtdIns4P in NPC1 patient cells. Interestingly, we also find that knockdown of DHHC3 or PI4KIIα in NPC1-deficient cells significantly reduces lysosomal PtdIns4P, an observation consistent with its presence at lysosome membranes. This model is supported by our own report of DHHC3 and PI4KIIα on lysosomes, and independent reports of PI4KIIα (Lim et al., 2019), as well as other DHHC5 and DHHC20 palmitoyl acyltransferases (Liu et al., 2018; Lim et al., 2019), on lysosome membranes and suggests DHHC-dependent recruitment of PI4KIIα to lysosomes could be a mechanism for tuning lysosomal PtdIns4P levels. As noted, under normal cellular conditions PI4KIIα appears to be fully palmitoylated and essentially acts as an integral membrane protein. This means that NPC1-mediated increases in Golgi or lysosome PI4KIIα likely occur as a consequence of reductions in PI4KIIα at other subcellular compartments. Our data suggest loss of PI4KIIα from early endosome compartments may provide the substrate for DHHC3 to elevate levels at Golgi and lysosome membranes. Future experiments are required to rigorously test this hypothesis.

In the case of PI4KIIβ, our analysis details an important role for ACBD3 in facilitating the increases in Golgi and lysosome PtdIns4P, consistent with reports specifying interactions between the N-terminus of PI4KIIβ and ACBD3 (Sasaki et al., 2012; Klima et al., 2016). Despite its crucial role in recruiting PI4KIIβ to the Golgi, there are only a few reports of it being localized to lysosome membranes (White et al., 2016; Liu et al., 2018). Our super-resolution imaging analysis determined that the cellular fraction of ACBD3 coincident with LAMP1 and PI4KIIβ levels are both significantly elevated at lysosome membranes following loss of NPC1 function. Furthermore, we find that knockout of either ACBD3 or PI4KIIβ significantly reduces PtdIns4P levels across different cells lacking NPC1 function. These data are consistent with a NPC1-dependent mechanism that facilitates ACBD3-mediated recruitment of PI4KIIβ to lysosome membranes. It should be noted that we also see an elevation in the abundance of ARF1 at Golgi membranes. This is important because it has been proposed that ACBD3 controls the Golgi recruitment of PI4KIIβ, which in turn recruits c10orf76 to influence the dynamics and localization of Arf1-GTP, to activate PI4KIIβ (McPhail et al., 2019). Thus, the observed increases in Golgi PI4KIIβ and PtdIns4P could be under the dual regulation of ACBD3 and ARF1 in NPC1 disease. It should be noted that in our experiments we use overexpression and knockdown of proteins to test a role for ACBD3 and DHHC3 in recruiting PI4K enzymes to Golgi and lysosomal membranes. These approaches offer ways to dramatically increase or decrease protein levels to test their involvement in facilitating increases in PtdIns4P levels following loss of NPC1 function. Future experiments, that precisely titrate protein levels to the same magnitude as observed in NPC1 loss of function cells, will be required to fully test whether changes in recruitment of these proteins to Golgi or lysosome membranes are necessary or sufficient for the observed changes in PtdIns4P levels, trafficking, and mTORC1 recruitment.

A key question remaining is the molecular timing of PtdIns4P increases at Golgi and lysosome membranes following loss of NPC1 function. We offer three simple, and certainly not exhaustive models. First, the simplest interpretation is that both enzymes are concurrently recruited to each organelle membrane to elevate PtdIns4P levels. This model is supported by the presence of recruitment machinery and enzymes at both organelles. An alternative model involves PI4KIIα/IIβ synthesizing PtdIns4P only at Golgi membranes, with exiting vesicles entering the endolysosomal pathway having excess PtdIns4P. If correct, the fraction of PI4KIIα/IIβ we observe on lysosomes would merely be coincident with PtdIns4P elevations and thus would likely not have local access to their PtdIns4P substrate. In a final, sequential model, influenced by the Balla group (Jović et al., 2012), ACBD3-Pi4KIIβ generates PtdIns4P at the Golgi, to allow for efficient exit of cargo destined for lysosomes, while DHHC3-Pi4KIIα generates PtdIns4P on late endosomes.
to enable efficient cargo transport to lysosomes. Here, the compound elevations in PtdIns4P levels would sequentially increase PtdIns4P levels across the endolysosomal pathway. Each of these models offers several interesting avenues for future exploration.

An intriguing observation in the course of our studies is the fluidity of proteins within membrane-membrane contact sites (MCS). While much research has characterized the identity of many of the proteins within ER-TGN and ER-lysosome MCS, little is known about the molecular choreography of these proteins and how exactly they are modified during pathophysiological conditions. Here we show that loss of NPC1 function leads to a functional reorganization of key components of the cholesterol/PtdIns4P cycle and represents one of the first reported examples of fine-tuning of these transfer portals in disease. Our data reveal enhanced recruitment of OSBP, VAPA, and SAC1 to ER-TGN MCS in cells harboring NPC1 disease mutations. We suggest the molecular rearrangement of these MCS proteins likely occurs downstream of PI4K-dependent generation of Golgi PtdIns4P. In our model, increased Golgi or lysosome PtdIns4P levels would recruit OSBP through binding of its PH domain to PtdIns4P, while interactions with VAP would engage the ER. Increased tethering of OSBP at MCS would amplify PtdIns4P and cholesterol transport to ER and donor membranes, respectively. This leaves SAC1 the crucial task of dephosphorylating transferred PtdIns4P to PtdIns on ER membranes. This key step ensures the maintenance of the steep PtdIns4P gradient and positions SAC1 as key regulator of the OSBP cycle. Key questions remain for the cholesterol/PtdIns4P cycle in NPC1 disease, such as, (i) what effect does altered NPC1 and OSBP function have on TGN cholesterol? (ii) What influence do cholesterol levels at ER and TGN membranes have on cholesterol sensitive proteins like PI4KIIα (Waugh et al., 2006) or membrane proteins like VAPA and SAC1, that are well positioned to sense variations in cholesterol levels (Wakana et al., 2021), and (iii) how are PI4KIIα and IIIβ spatially and temporally coupled at ER-TGN MCS to organize cholesterol and PtdIns4P transport?

In the context of NPC1 disease, as in other cancers/aging/neurological disorders (Condon & Sabatini, 2019), the recruitment of mTORC1 to lysosomes membranes would initiate aberrant growth pathways leading to inhibition of essential autophagic clearing functions and buildup of toxic metabolites. In NPC disease, the sequence of events leading to mTORC1 recruitment to lysosome membranes begins with reduced cholesterol efflux across the lysosome membrane leading to the initiation of the following pervasive signaling reaction: (i) increased PI4K-dependent production of PtdIns4P (this manuscript), (ii) increased lysosomal PtdIns4P facilitates increased engagement of OSBP at ER-lysosome MCS (Lim et al., 2019), leading to (iii) a steeper PtdIns4P gradient to drive cholesterol transport from the ER to lysosome membrane (Mesmin et al., 2013; Lim et al., 2019), thereby (iv) assisting in the recruitment of mTORC (Castellano et al., 2017; Lim et al., 2019). It should be noted that previous work, using similar cell lines, demonstrated that both recruitment and downstream activity of mTORC1 are increased following loss of NPC1 function (Castellano et al., 2017; Lim et al., 2019). We show that mTORC1 recruitment is altered following knockdown of ACBD3, careful investigations are still required to dissect the downstream consequences of PI4K-mediated mTORC activity. mTOR has also been demonstrated to contribute to SREBP activation, by controlling the nuclear entry of Lipin-1 (Peterson et al., 2011). Activated mTORC1 has been shown to phosphorylate lipin 1 to retain it in the cytoplasm, allowing nuclear SREBP binding to target genes resulting in increased lipogenesis. In the context of our data detailing a potential role for SREBP in enhancing the recruitment of PI4K enzymes, mTORC1 activation may remove an inhibitory brake on SREBP target genes, to increase lysosomal PtdIns4P thereby strengthening and perpetuating mTORC1 recruitment.

It remains to be fully determined if NPC1-dependent increases in Golgi membrane PtdIns4P levels represent a cellular signaling pathway that compensates for altered cholesterol homeostasis to preserve cerebellar neuron integrity or destructively contributes to the death of vulnerable Purkinje neurons (Praggastis et al., 2015). Given that PI4K enzymes and PtdIns4P have been implicated across a wide range of neuronal functions and pathologies, including Gaucher disease (Jović et al., 2012), spinocerebellar degeneration (Simons et al., 2009), myelination (Alvarez-Prats et al., 2018), and Schizophrenia (Jungerius et al., 2008; Houlihan et al., 2009), our results suggest that the NPC1-dependent elevations in Golgi PtdIns4P leading to enhanced anterograde Golgi trafficking will likely be deleterious to neuronal fidelity. Lessons from cell biology and cancer inform us of the importance of regulated PtdIns4P-dependent trafficking events at the Golgi (reviewed Waugh (2019)) and how their dysfunction leads to alterations in the PtdIns4P protein interactome, a malignant secretory phenotype, and tumor progression.

In conclusion, we propose that lysosomal NPC1-mediated cholesterol efflux modulates the SREBP-dependent recruitment of PI4K enzymes to control the molecular organization of ER-TGN and ER-lysosome membrane contact sites, thereby tuning mTORC-dependent growth conditions and anterograde trafficking in health and disease. Collectively, this information presents intriguing possibility that similar to cancer, targeting these enzymes, their chaperones, substrates, and/or products in neurodegenerative disease, may offer therapeutic checkpoints for devising strategies to slow neuronal death and hence disease progression.

Materials and Methods

Reagents and Tools table

<table>
<thead>
<tr>
<th>Reagent or resource</th>
<th>Source</th>
<th>Identifier</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antibodies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rabbit polyclonal PI4KIIα</td>
<td>Abcam</td>
<td>Cat# ab71824; RRID: AB_1269758</td>
</tr>
<tr>
<td>Rabbit polyclonal PI4KIIα</td>
<td>P. De Camilli, Yale University School of Medicine, New Haven, CT</td>
<td>N/A</td>
</tr>
<tr>
<td>Mouse monoclonal PI4KIIα</td>
<td>Santa Cruz</td>
<td>Cat# sc-390026</td>
</tr>
</tbody>
</table>

The Authors
<table>
<thead>
<tr>
<th>Reagent or resource</th>
<th>Source</th>
<th>Identifier</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rabbit polyclonal PI4KIIβ</td>
<td>Abcam</td>
<td>Cat# ab109418; RRID: AB_10861028</td>
</tr>
<tr>
<td>Mouse monoclonal PI4KIIβ</td>
<td>BD Biosciences</td>
<td>Cat# 611816; RRID: AB_399296</td>
</tr>
<tr>
<td>Sheep polyclonal TGN46</td>
<td>Bio-Rad</td>
<td>Cat# AHP500GT; RRID: AB_2203291</td>
</tr>
<tr>
<td>Mouse monoclonal TGN46</td>
<td>Novus</td>
<td>Cat# NB101-49643; RRID: AB_10011762</td>
</tr>
<tr>
<td>Mouse monoclonal EEA1</td>
<td>BD Biosciences</td>
<td>Cat# 610456; RRID: AB_397829</td>
</tr>
<tr>
<td>Mouse monoclonal Rab7</td>
<td>Santa Cruz Biotechnology</td>
<td>Cat sc-271608; RRID: AB_10649046</td>
</tr>
<tr>
<td>Mouse monoclonal β-actin</td>
<td>J. Trimmer, UC Davis, Davis, CA</td>
<td>N/A</td>
</tr>
<tr>
<td>GAPDH</td>
<td>Proteintech</td>
<td>10494-1-AP</td>
</tr>
<tr>
<td>Rabbit polyclonal OSBP</td>
<td>Atlas antibodies</td>
<td>Cat# HPA039227; RRID: AB_2676401</td>
</tr>
<tr>
<td>Rabbit polyclonal DHHC3</td>
<td>Abcam</td>
<td>Cat# ab31837; RRID: AB_742236</td>
</tr>
<tr>
<td>Rabbit polyclonal SAC1</td>
<td>Atlas Antibodies</td>
<td>Cat# sc-101277; RRID: AB_2273355</td>
</tr>
<tr>
<td>Mouse monoclonal Giantin</td>
<td>Abcam</td>
<td>Cat# ab37266; RRID: AB_880195</td>
</tr>
<tr>
<td>Rabbit polyclonal Giantin</td>
<td>BioLegend</td>
<td>Cat# 924302; RRID: AB_2565451</td>
</tr>
<tr>
<td>Mouse monoclonal Lamp1</td>
<td>Abcam</td>
<td>Cat# ab25630; RRID: AB_470708</td>
</tr>
<tr>
<td>Rabbit polyclonal Lamp2</td>
<td>Invitrogen</td>
<td>Cat# PA1-655; RRID: AB_2134625</td>
</tr>
<tr>
<td>Rabbit monoclonal mTOR</td>
<td>Cell Signaling Technology</td>
<td>Cat# 29835</td>
</tr>
<tr>
<td>Goat anti-Mouse, Alexa Fluor 647</td>
<td>Invitrogen</td>
<td>Cat# A-21236; RRID: AB_141725</td>
</tr>
<tr>
<td>Goat anti-Rabbit, Alexa Fluor 488</td>
<td>Invitrogen</td>
<td>Cat# A-11034; RRID: AB_2576217</td>
</tr>
<tr>
<td>Donkey anti-Sheep, Alexa Fluor 555</td>
<td>Invitrogen</td>
<td>Cat# A-21436; RRID: AB_2535857</td>
</tr>
<tr>
<td>Goat anti-Rabbit 680RD</td>
<td>Li-COR Biosciences</td>
<td>Cat# 926-68071; RRID: AB_10956166</td>
</tr>
<tr>
<td>Goat anti-Mouse 800CW</td>
<td>Li-COR Biosciences</td>
<td>Cat# 925-32210; RRID: AB_2687825</td>
</tr>
<tr>
<td>Chemicals, peptides, and recombinant proteins</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B27</td>
<td>Gibco</td>
<td>Cat#17504-044</td>
</tr>
<tr>
<td>Glutamax</td>
<td>Gibco</td>
<td>Cat#35050-061</td>
</tr>
<tr>
<td>Cytosine-β-arabinofuranoside</td>
<td>Millipore</td>
<td>Cat#251010</td>
</tr>
<tr>
<td>U18666A</td>
<td>Sigma-Aldrich</td>
<td>Cat#U3633</td>
</tr>
<tr>
<td>PF-429242</td>
<td>Tocris</td>
<td>Cat#3354</td>
</tr>
<tr>
<td>Lipofectamine 2000</td>
<td>Invitrogen</td>
<td>Cat#11668-027</td>
</tr>
<tr>
<td>Lipofectamine LTX</td>
<td>Invitrogen</td>
<td>Cat#15338-030</td>
</tr>
<tr>
<td>Lipofectamine RNAiMAX</td>
<td>Invitrogen</td>
<td>Cat#13778-030</td>
</tr>
<tr>
<td>Paraformaldehyde</td>
<td>Electron Microscopy Sciences</td>
<td>Cat#15710</td>
</tr>
<tr>
<td>Glutaraldehyde</td>
<td>Sigma</td>
<td>Cat# G7651</td>
</tr>
<tr>
<td>Filipin</td>
<td>Sigma</td>
<td>Cat#F9765</td>
</tr>
<tr>
<td>SEA BLOCK Blocking Buffer</td>
<td>Thermo Scientific</td>
<td>Cat# 37527</td>
</tr>
<tr>
<td>Complete Mini protease inhibitor cocktail</td>
<td>Roche</td>
<td>Cat# 1183617001</td>
</tr>
<tr>
<td>PowerUp SYBR Green Master Mix</td>
<td>Thermo Fisher Scientific</td>
<td>Cat#A25742</td>
</tr>
<tr>
<td>Critical commercial assays</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pierce BCA Protein Assay Kit</td>
<td>Thermo Fisher</td>
<td>Cat# 23225</td>
</tr>
<tr>
<td>AffinityScript QPCR Synthesis Kit</td>
<td>Agilent technologies</td>
<td>Cat#600559</td>
</tr>
<tr>
<td>RNeasy Plus Mini Kit</td>
<td>Qiagen</td>
<td>Cat#74134</td>
</tr>
<tr>
<td>Experimental models: cell lines</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control patient-derived fibroblasts</td>
<td>Coriell Institute</td>
<td>Cat# GM05659</td>
</tr>
<tr>
<td>NPC1&lt;sup&gt;100237&lt;/sup&gt; patient-derived fibroblasts</td>
<td>Coriell Institute</td>
<td>Cat# GM18453</td>
</tr>
</tbody>
</table>
### Reagents and Tools table (continued)

<table>
<thead>
<tr>
<th>Reagent or resource</th>
<th>Source</th>
<th>Identifier</th>
</tr>
</thead>
<tbody>
<tr>
<td>NPC1&lt;sup&gt;−/−&lt;/sup&gt; CHO cell line</td>
<td>Millard et al (2000)</td>
<td>N/A</td>
</tr>
<tr>
<td>HEK293 Cas9 cell line</td>
<td>ATCC</td>
<td>Cat# CRL-1573Cas9</td>
</tr>
<tr>
<td>HEK293 eGFP-Sac</td>
<td>Zewe et al (2018)</td>
<td>N/A</td>
</tr>
<tr>
<td>tsA201 Cell Line</td>
<td>Sigma</td>
<td>Cat# 96121229</td>
</tr>
<tr>
<td>Experimental models: organisms/strains</td>
<td></td>
<td></td>
</tr>
<tr>
<td>E18 mouse embryos</td>
<td>JAX</td>
<td></td>
</tr>
<tr>
<td>Oligonucleotides</td>
<td></td>
<td></td>
</tr>
<tr>
<td>sgRNA targeting PI4K2A sequence: CCATTGACCGACTGAGTGAAGTCC</td>
<td>Integrated DNA Technologies</td>
<td>N/A</td>
</tr>
<tr>
<td>sgRNA targeting PI4K3B sequence: CCACCTCAACGACACTCCCGT</td>
<td>Integrated DNA Technologies</td>
<td>N/A</td>
</tr>
<tr>
<td>sgRNA targeting ACBD3 sequence: GAGCTTGACAAACTCCACCA</td>
<td>Integrated DNA Technologies</td>
<td>N/A</td>
</tr>
<tr>
<td>sgRNA targeting DHHC3 sequence: CGGAATTGTGTTCAACCTGC</td>
<td>Integrated DNA Technologies</td>
<td>N/A</td>
</tr>
<tr>
<td>PrimeTime qPCR PI4KI&lt;sup&gt;a&lt;/sup&gt; Primers:</td>
<td>Integrated DNA Technologies</td>
<td>Hs.PT.58.733616</td>
</tr>
<tr>
<td>PrimeTime qPCR PI4KI&lt;sup&gt;b&lt;/sup&gt; Primers:</td>
<td>Integrated DNA Technologies</td>
<td>Hs.PT.58.14990511</td>
</tr>
<tr>
<td>PrimeTime qPCR ACBD3 Primers</td>
<td>Integrated DNA Technologies</td>
<td>Hs.PT.58.26724987</td>
</tr>
<tr>
<td>PrimeTime qPCR DHHC3 Primers</td>
<td>Integrated DNA Technologies</td>
<td>Hs.PT.58.45384099</td>
</tr>
<tr>
<td>PrimeTime qPCR HPRT Primers</td>
<td>Integrated DNA Technologies</td>
<td>Hs.PT.58v.45621572</td>
</tr>
<tr>
<td>Recombinant DNA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P4M-YFP</td>
<td>Kruse et al (2016)</td>
<td>N/A</td>
</tr>
<tr>
<td>pGFP-P4M</td>
<td>Hammond et al (2014)</td>
<td></td>
</tr>
<tr>
<td>mCherry-P4M</td>
<td>Hammond et al (2014)</td>
<td>N/A</td>
</tr>
<tr>
<td>GFP-tagged PI4K&lt;sub&gt;I&lt;sup&gt;a&lt;/sub&gt;&lt;/sup&gt; and PI4K&lt;sub&gt;I&lt;sup&gt;b&lt;/sup&gt;&lt;/sub&gt;</td>
<td>Balla et al (2002)</td>
<td>N/A</td>
</tr>
<tr>
<td>GFP-DHHC3</td>
<td>This paper</td>
<td>N/A</td>
</tr>
<tr>
<td>GFP-ACBD3</td>
<td>This paper</td>
<td>N/A</td>
</tr>
<tr>
<td>HA-tagged DHHC3, DHHC7 (C157S), DHHC7, DHHC7 (C1605) and G5D</td>
<td>Fukata et al (2004)</td>
<td>N/A</td>
</tr>
<tr>
<td>LAMP1-RFP</td>
<td>Addgene</td>
<td>Cat#1817</td>
</tr>
<tr>
<td>LAMP1-mGFP</td>
<td>Addgene</td>
<td>Cat#34831</td>
</tr>
<tr>
<td>LAMP1-CFP</td>
<td>Addgene</td>
<td>Cat#34831</td>
</tr>
<tr>
<td>SEC61β-mCherry</td>
<td>Dickson et al (2016)</td>
<td>N/A</td>
</tr>
<tr>
<td>OSH1-CFP</td>
<td>Szentpetery et al (2010)</td>
<td>N/A</td>
</tr>
<tr>
<td>2xFLAG-SREBP-1a</td>
<td>Addgene</td>
<td>Cat#26801</td>
</tr>
<tr>
<td>Str-Golgin84_VSVG-SBP-EGFP</td>
<td>Addgene</td>
<td>Cat#65305</td>
</tr>
<tr>
<td>Str-KDEL_TNF-SBP-mCherry</td>
<td>Addgene</td>
<td>Cat#65279</td>
</tr>
<tr>
<td>Software and algorithms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ImageJ</td>
<td>NIH</td>
<td><a href="https://imagej.nih.gov/ij/">https://imagej.nih.gov/ij/</a></td>
</tr>
<tr>
<td>Micro-manager</td>
<td>NIH</td>
<td><a href="https://micro-manager.org">https://micro-manager.org</a></td>
</tr>
<tr>
<td>ZEN imaging software</td>
<td>Zeiss</td>
<td>RRID: SCR_013672</td>
</tr>
<tr>
<td>Masslynx software</td>
<td>Waters</td>
<td>RRID: SCR_014271</td>
</tr>
<tr>
<td>GraphPad Prism8</td>
<td>GraphPad</td>
<td>RRID:SCR_002798</td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Polyacrylamide Bis-Tris gel</td>
<td>Invitrogen</td>
<td>Cat# NW04120BOX</td>
</tr>
<tr>
<td>Polyvinylidene difluoride membrane</td>
<td>Life Technologies</td>
<td>Cat# LC2000</td>
</tr>
</tbody>
</table>
**Methods and Protocols**

### Cell culture

All the cell lines were incubated at 37°C and 5% CO₂ and subcultured twice weekly. Patient fibroblasts from an apparently healthy male (control) and a male with a homozygous mutation in NPC1 were purchased from Coriell Institute and were grown in Eagle’s Minimum Essential Medium (MEM) supplemented with 2 mM L-glutamine, 10% FBS and 0.2% penicillin/streptomycin. Control, NPC1−/− (Millard et al., 2000), and SRD-13A CHO cells (Rawson et al., 1999) (SCAP−/−) (kindly provided by D. Ory, Washington University, St. Louis, MO), HEK293 cells that stably express Cas9 (HEK293-CAS9) were purchased from ATCC (CRL-1573Cas9). tsA201 cells were cultured in DMEM-based proliferation medium containing 10% FBS and 0.2% penicillin/streptomycin. HEK293 cells stably expressing eGFP11-Sac1 and eGFP11-Sec61 were kindly provided by G. Hammond (Zewe et al., 2018) (University of Pittsburgh School of Medicine, Pittsburgh, PA) and were cultured in the same way as tsA201 cells. COS7 cells were a kind gift from Dr. Jodi Nunnari (University of California, Davis). All cells were seeded on 1.5 glass coverslips 2 to 4 days prior imaging or fixation. Hippocampal neurons were isolated and cultured as previously described (Tiscione et al., 2019). Briefly, hippocampi were dissected from E18 mouse embryos and treated for 20 min at 37°C in Hank’s solution containing 0.25% trypsin, followed by mechanical dissociation. Isolated neurons were plated on coverslips coated with poly-L-lysine and cultured in Neurobasal supplemented with B27, Glutamax, 5% FBS, and 0.2% penicillin/streptomycin. After 7 days in vitro (DIV), cytosine-D-arabinofuranoside (251010; Millipore) was added to neuronal cultures to inhibit astrocyte growth. For inhibition of NPC1 activity and LAMP pathway, cells were treated for 24 h prior imaging with 10 μM U18666A and/or 10 μM PF-429242, respectively.

### Plasmid and sgRNA transfections

Plasmids encoding the following proteins were used: P4M-YFP (Kruse et al., 2016), mCherry-P4M (Hammond et al., 2014), eGFP-P4M (Hammond et al., 2014), GFP-tagged P4KIIα and P4KIIβ (kind gift from Tamas Balla, NIH, Bethesda, MD) (Balla et al., 2002), HA-tagged DHHC3, DHHC3 (C157S), DHHC7, DHHC7 (C160S) and GSD (kindly provided by M. Fukata, National Institute for Physiological Sciences, Okazaki, Japan) (Fukata et al., 2004), pLAMP1-mCherry, pLAMP1-mGFP, OSH1-GFP (Szentpetery et al., 2010), 2xFLAG-SREBP-1a (Addgene: 26801), Str-Goigin84_VSVG-SBP-EGFP, StrKDEL_TNF-SBP-mCherry (Boncompain et al., 2012). In addition, GFP-DHHC3 (Accession No: NM_016598.3) and GFP-ACBD3 (NM_022735.4) were cloned into pcDNA3.1(+)-N-eGFP: 5’: cloning site KpnI, 3’ Cloning Site: BamHI. Transfections of cDNAs (0.5 to 1 μg) were performed 24 h prior imaging using either Lipofectamine 2000 for hippocampal neurons, CHO and tsA201 cells, or Lipofectamine LTX for fibroblasts. To generate gene knockouts, short guide RNAs targeting P4KIIα, P4KIIβ, DHHC3, and ACBD3 were transfected in Cas9-expressing HEK293 cells along with a fluorescent transfection marker using Lipofectamine RNAiMAX and incubated for 48–72 h before imaging. Reduction in gene products was validated by Western blot and immunofluorescence analysis (Fig EV3). A limitation of this approach is that it does not generate knockout cell lines rather results in 70–90% knockdown of protein products.

### Filipin staining and imaging

Cholesterol was stained according to a previously described procedure (Vivas et al., 2019). Cells were first fixed with 4% paraformaldehyde and 0.1% glutaraldehyde in phosphate-buffered saline (PBS) for 10 min at room temperature, before being incubated for 2 h at room temperature in PBS containing filipin at 3 mg/ml. After 5 × 5 min washes in PBS, cells were imaged in PBS under a Zeiss 880 AiryScan confocal microscope. Filipin fluorescence was visualized using 405 nm excitation.

### Immunofluorescence labeling

Cells were fixed for 10 min at room temperature in PBS with 3% paraformaldehyde and 0.1% glutaraldehyde and blocked for 1 h in 50% SEA BLOCK Blocking Buffer and 0.5% Triton X-100 in PBS. After 5 × 5 min washes in PBS washes, cells were incubated overnight at 4°C in 20% SEA BLOCK and 0.5% Triton X-100 in PBS with the following primary antibodies: rabbit polyclonal P4KIIα (1:250, kindly provided by Pietro De Camilli, Yale University School of Medicine, New Haven, CT), mouse monoclonal P4KIIα (1:50), mouse monoclonal P4KIIβ (1:25), sheep polyclonal TGN46 (1:100), mouse monoclonal TGN46 (1:400), mouse monoclonal EEA1 (1:25), mouse monoclonal RAB7 (1:50), rabbit polyclonal OSBP (1:100), mouse monoclonal VAPA (hybridoma culture supernatant: 1:5; kindly provided by J. Trimmer, UC Davis, Davis, CA), rabbit polyclonal DHHC3 (1:50), rabbit polyclonal SAC1 (1:100), mouse monoclonal ACBD3 (1:50), mouse monoclonal Giatin (1:500), rabbit polyclonal Giatin (1:100), rabbit polyclonal Lamp2 (1:00), and mouse monoclonal Lamp1 (1:20). For immunofluorescence detection, cells were incubated with Alexa Fluor 488 anti-rabbit (1:1,000), Alexa Fluor 555 anti-Sheep (1:1,000), and Alexa Fluor 647 anti-mouse (1:1,000) secondary antibodies for 1 h at room temperature in the dark.

### Super-resolution confocal microscopy

Imaging was conducted at room temperature with a Zeiss LSM880 confocal laser scanning microscope equipped with a Plan-Apochromat 63× Oil DIC M27 objective (N.A. 1.4) and a super-resolution Airyscan detection unit. Images of GFP/Alexa-488, YFP, mCherry, and Alexa-647 were collected using the 488, 514, 594, and 633 nm excitation lines, respectively, with multicolor images sequentially acquired. Live and fixed cells were imaged in PBS or Ringer’s solution (in mM, 160 NaCl, 2.5 KCl, 2 CaCl₂, 1 0 MgCl₂, 10 HEPES, and 8 D-Glucose). For all acquisitions, images were taken at 0.5 μm depth intervals within the cell and were subsequently corrected using the Airyscan processing toolbox in ZEN software. Analysis was carried out with ImageJ (NIH, Bethesda, MD, USA). Briefly, z-stack images were collapsed to single maximum intensity projection images. After background subtraction, mean fluorescence intensity was measured within a region of interest (ROI) and normalized to the cytoplasm mean fluorescence intensity. For colocalization / overlap analyses, binary masks of TGN38/46, Giatin, or Lamp1 images were used to measure P4M, P4K enzymes, VAPA, OSBP, SAC1, and SEC61β fluorescence intensities.

### RUSH trafficking assay

Membrane trafficking was assessed by means of the retention using selective hooks (RUSH) system (Boncompain et al., 2012). Briefly, live imaging in tsA201 cells expressing Str-KDEL_TNF-SBP-mCherry...
or Str-Golgin84_VSVG-SBP-EGFP was performed using a combined Andor W-1 spinning disk confocal microscope and Olympus Cell total internal reflected fluorescence (TIRF) system, equipped with a Photometrics Prime 95B camera and a stage-top temperature and CO₂-controlled incubator (Okolab). Cells were excited either with 488-nm or 561-nm lasers, and confocal or TIRF images were collected through a 63× (1.4 NA) Olympus objective, using Micromanager software. All images were acquired at 37°C in phenol red-free DMEM with a frequency of 2 frames per min. D-Biotin (80 µM) was added in the experimental chamber after 1–2 min of acquisition. Image analysis was performed using ImageJ software.

**Quantitative polymerase chain reaction**
The RNA transcripts from control and NPC1 patient fibroblasts were first extracted using RNeasy Plus Mini Kit before being converted into cDNA with an AffinityScript qPCR cDNA Synthesis Kit. Quantitative real-time PCR was performed in triplicate using the PowerUp SYBR Green Master Mix. The following pre-made S′ nuclease assays were used: PI4K2A (Hs.PT.58.73616); PI4KB (Hs.PT.58.1499051); ACBD3 (Hs.PT.58.26724987); ZDHHC3 (Hs.PT.58.45384099); HPRT (Hs.PT.58v.45621572). HPRT was used as a reference to normalize PCR products.

**Western blotting**
Patient fibroblasts, HEK293 Cas9, and tsA201 cells were homogenized on ice in RIPA lysis buffer supplemented with complete Mini protease inhibitor cocktail. After centrifugation (20,400 g, 4°C, 25 min), the concentration of protein lysates in the supernatant was determined using Pierce BCA Protein Assay Kit. Protein samples were separated on 4 to 12% polyacrylamide Bis-Tris gel for 1h15 at 155V and electrophoretically blotted onto polyvinylidene difluoride membranes using a Mini-Bolt system (A25977; Thermo Fisher Scientific). After 1 h incubation at room temperature in TBS buffer supplemented with 0.05% Tween-20 (TBS–T) and 7% non-fat dry milk, membranes were exposed overnight at 4°C to the following primary antibodies in TBS-Tween-20 0.05%: mouse monoclonal β-actin, GAPDH, rabbit polyclonal PI4Kιζ, rabbit polyclonal PI4Kιη, rabbit polyclonal OSBP, rabbit polyclonal SAC1, mouse monoclonal ACBD3. Membranes were washed in TBS-Tween-20 0.05% and incubated for 1 h at room temperature with fluorescent secondary antibodies: goat anti-rabbit 680RD and goat anti-Mouse 800CW. Signals were detected using Saphire Gel Imager (Azure Biosystems) and quantified using ImageJ software.

**Lipid mass spectrometry**
Phosphoinositide levels were quantified by a refined mass spectrometry procedure, as described previously (Traynor-Kaplan et al., 2017; Vivas et al., 2019). Briefly, endogenous lipids from brain samples and internal standards were extracted with n-butanol and chloroform. After methylation-mediated derivatization, samples were subjected to a C4 column in an acetonitrile formic acid gradient. Post-column eluate was infused with sodium formate and then subjected to a C4 column in an acetonitrile formic acid gradient. Lipid mass spectrometry data produced in this study are available at MetaboLights database with the following ID: MTBLS2612 (http://www.ebi.ac.uk/metabolights/MTBLS2612).

**Conflict of interest**
The authors declare that they have no conflict of interest.
References


Zewe JP, Wills RC, Sangappa S, Goulden BD, Hammond GR (2018) SAC1 degrades its lipid substrate PtdIns4P in the endoplasmic reticulum to maintain a steep chemical gradient with donor membranes. Elife 7: e35588


Wei YJ, Sun HQ, Yamamoto M, Wlodarski P, Kunii K, Martinez M, Barylko B, Albanesi JP, Yin HL (2002) Type II phosphatidylinositol 4-kinase beta is a cytosolic and peripheral membrane protein that is recruited to the plasma membrane and activated by Rac-GTP. J Biol Chem 277: 46586 – 46593


License: This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.